Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma

Abstract

In this survey study of the E1A11 trial, worse GP5 response was associated with ETD. These findings suggest that simple assessment of adverse-effect bother while receiving treatment is an efficient way to indicate treatment tolerability and ETD risk.